Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
EVAX Stock | USD 1.66 0.09 5.73% |
Slightly above 64% of all Evaxion Biotech's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Evaxion Biotech AS suggests that some traders are interested. Evaxion Biotech's investing sentiment can be driven by a variety of factors including economic data, Evaxion Biotech's earnings reports, geopolitical events, and overall market trends.
Evaxion |
11 out of 16 patients had objective clinical responses, equaling a 69 percent Overall Response Rate15 out of the 16 patients had a reduction of their tumors 79 percent of EVX-01s vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches A positive correlation was observed between the AI-Immunology platform predictions and neoantigen immune response EVX-01 as a novel potential melanoma treatment holds a significant com
Read at finance.yahoo.com
Evaxion Biotech Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Evaxion Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evaxion Biotech Fundamental Analysis
We analyze Evaxion Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evaxion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evaxion Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Evaxion Biotech is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Evaxion Biotech AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evaxion Biotech stock to make a market-neutral strategy. Peer analysis of Evaxion Biotech could also be used in its relative valuation, which is a method of valuing Evaxion Biotech by comparing valuation metrics with similar companies.
Peers
Evaxion Biotech Related Equities
BDRX | Biodexa Pharmaceticals | 14.00 | ||||
GLUE | Monte Rosa | 13.72 | ||||
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
PHIO | Phio Pharmaceuticals | 3.03 | ||||
RNAZ | Transcode Therapeutics | 2.94 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
ZURA | Zura Bio | 1.67 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
LYEL | Lyell Immunopharma | 1.10 | ||||
ALLR | Allarity Therapeutics | 0.90 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
VRAX | Virax Biolabs | 4.83 |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.